BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm that responds poorly to chemotherapy. Although treatment with pemetrexed in combination with cisplatin serves as first-line chemotherapy for MPM, the optimal second-line and beyond therapy has not yet been fully examined. METHODS: Between March 2008 and October 2011, 17 consecutive Japanese patients pretreated with at least one regimen of platinum plus pemetrexed chemotherapy received gemcitabine and vinorelbine. Responses, survival time, and toxicity were retrospectively evaluated. RESULTS: Response [partial response (PR) + complete response (CR)] and disease control [stable disease (SD) + PR + CR] rates were 18 and 82 %, respectively. The median progression-free survival (PFS) after combination chemotherapy was 6.0 months, whereas the median overall survival (OS) was 11.2 months. Grade 3 or 4 neutropenia and anemia were observed in 41 and 29 % of patients, respectively, and one patient experienced febrile neutropenia. Grade 3 or 4 nonhematologic toxicities included constipation (6 %) and phlebitis (6 %). CONCLUSION: Combination chemotherapy using gemcitabine with vinorelbine was shown to have moderate activity in Japanese MPM patients pretreated with platinum plus pemetrexed chemotherapy. A further multicenter phase II trial is warranted to confirm the efficacy and safety of this combination treatment.
BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive neoplasm that responds poorly to chemotherapy. Although treatment with pemetrexed in combination with cisplatin serves as first-line chemotherapy for MPM, the optimal second-line and beyond therapy has not yet been fully examined. METHODS: Between March 2008 and October 2011, 17 consecutive Japanese patients pretreated with at least one regimen of platinum plus pemetrexed chemotherapy received gemcitabine and vinorelbine. Responses, survival time, and toxicity were retrospectively evaluated. RESULTS: Response [partial response (PR) + complete response (CR)] and disease control [stable disease (SD) + PR + CR] rates were 18 and 82 %, respectively. The median progression-free survival (PFS) after combination chemotherapy was 6.0 months, whereas the median overall survival (OS) was 11.2 months. Grade 3 or 4 neutropenia and anemia were observed in 41 and 29 % of patients, respectively, and one patient experienced febrile neutropenia. Grade 3 or 4 nonhematologic toxicities included constipation (6 %) and phlebitis (6 %). CONCLUSION: Combination chemotherapy using gemcitabine with vinorelbine was shown to have moderate activity in Japanese MPM patients pretreated with platinum plus pemetrexed chemotherapy. A further multicenter phase II trial is warranted to confirm the efficacy and safety of this combination treatment.
Authors: D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer Journal: J Thorac Cardiovasc Surg Date: 1999-01 Impact factor: 5.209
Authors: E H Tan; A Szczesna; M Krzakowski; H N Macha; U Gatzemeier; K Mattson; M Wernli; P Reiterer; R Hui; J Von Pawel; O Bertetto; J C Pouget; J P Burillon; Y Parlier; R Abratt Journal: Lung Cancer Date: 2005-08 Impact factor: 5.705
Authors: Suresh S Ramalingam; Chandra P Belani; Christopher Ruel; Paul Frankel; Barbara Gitlitz; Marianna Koczywas; Igor Espinoza-Delgado; David Gandara Journal: J Thorac Oncol Date: 2009-01 Impact factor: 15.609
Authors: Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto Journal: Lancet Oncol Date: 2011-06-30 Impact factor: 41.316
Authors: C Raynaud; L Greillier; J Mazieres; I Monnet; B Mastroianni; G Robinet; G Fraboulet; A Dixmier; H Berard; R Lamy; J Letreut; H Lena; G Oliviero; S Botta; A Vergnenegre; I Borget; C Chouaid Journal: BMC Cancer Date: 2015-11-06 Impact factor: 4.430